ADC Payload
Leveraging the unique biodistribution and intracellular metabolism of ADCs, payloads can be precisely delivered to target cells and released following internalization, exerting potent anti-tumor effects. Consequently, ADC payloads are typically highly potent and structurally complex toxins, whose multi-step synthesis poses significant challenges. The requirement for advanced containment systems to safely handle highly potent materials further increases process complexity and cost.
At ChemExpress, we fully recognize these challenges. With deep process chemistry expertise, we have established multiple robust synthetic routes for complex ADC payloads and continuously optimized critical reaction steps to improve efficiency, scalability, and cost-effectiveness.
One-Stop ADC
CDMO Service
ChemExpress offers integrated services spanning from Payload-Linker to ADC DS&DP, enabling efficient scale-up and seamless technology transfer, effectively reducing management and transition costs.
Extensive Project Experience
& Comprehensive Inventory
Over 80 CMC projects, 6 BLA projects, and 1 commercial project have been delivered. 16 ADC payloads and related intermediates are registered with the FDA as DMFs.
Expert Scientific
Team
Our team of over 700 scientists provides comprehensive support from R&D to commercialization, ensuring high-quality, scalable solutions for your ADC pipeline.
Our Services
Our facilities support flexible Non-GMP& GMP payload production from milligram to kilogram scale with over 150 payloads in stock—enabling faster project initiation and seamless progression.
Categories of ADC payloads
Currently, ADC payloads approved for clinical use can be broadly classified into three major categories: microtubule inhibitors, DNA-damaging agents, topoisomerase I (TOP1) inhibitors. Meanwhile, emerging payload modalities, such as RNA polymerase inhibitors and immune agonists, are rapidly advancing, further expanding the landscape of ADC innovation.
| Category | Payloads | Representative Products |
|---|---|---|
| Microtubule Inhibitor | Maytansinoid | DM1, DM3, DM4 |
| Auristatins | MMAE,MMAD, MMAF | |
| Eribulin Derivatives | Eribulin Mesylate | |
| DNA Alkylating Agent | Pyrrolobenzodiazepines | PBD Dimer |
| Topoisomerase (TOP1) Inhibitor | Calicheamicin | / |
| Duocarmycin derivatives | DUBA | |
| Camptothecin Derivatives | SN-38, Exatecan derivatives (DXd) | |
| RNA Polymerase Inhibitor | Amanitin Derivatives | α-Amanitin |
| Immune Agonist | TLR Agonist | Resiquimod |
| STING Agonist | / |
Our Sites
R&D Sites
ADC Payload-Linker and Conjugation R&D, Route Confirmation, Process Optimization and GLP Toxicological Batch Production. 
ADC Payload-Linkers & HPAPIs Process Development and Manufacturing.
Related Services
ADC Payload Linker
We specialize in complex and novel payload-linker, offering fully customized synthesis, process development & optimization, clinical supply, and commercial manufacturing services to meet the specific needs of client projects.
ADC Linker
ChemExpress collaborates closely with clients to ADC linker screen, customized synthesis, process development & optimization, clinical supply, and commercial manufacturing to support advanced research worldwide.
FAQs
We support ADC payload programs from preclinical development through clinical supply and commercial manufacturing. Services can be customized to project stage, including route scouting, non-GMP toxicology batches, GMP clinical batches, and process validation for commercial manufacturing.
Our scalable manufacturing platform enables seamless transition across different development stage while maintaining quality and regulatory compliance.
Eribulin is a clinically validated microtubule inhibitor increasingly evaluated as an ADC payload. In recent years, process optimization and expanded manufacturing capacity have significantly improved its cost efficiency and supply reliability, enhancing its commercial feasibility for ADC programs.
From a development perspective, material demand depends on the project stage and conjugation strategy. IND-enabling toxicology studies typically require approximately 30-50 g, while GMP clinical manufacturing may require 50-100 g or more.
